ANALYTICAL CHEMISTRY AND STABILITY TESTING OF TREATMENT DRUGS

NIH GUIDE, Volume 22, Number 11, March 19, 1993



RFP AVAILABLE:  NO1DA-3-8301



P.T. 34



Keywords:

  Chemistry, Analytical 

  Drugs/Drug Abuse 

  Screening of Drugs/Agents 



National Institute on Drug Abuse



The National Institute on Drug Abuse (NIDA) is soliciting proposals

from qualified organizations having the capability to develop

analytical methods, carry out quality control tests, and perform

stability studies for the compounds and dosage forms to be used in the

medications development program.  The development of medications for

the treatment of drug addiction is a major mission of NIDA.  The NIDA

has been providing potential treatment drugs to investigators for use

in preclinical toxicology evaluation, pharmacological studies, and

clinical trials.  The treatment drugs include both bulk drug substances

(e.g., ibogaine, buprenorphine, naltrindole) and dosage forms (e.g.,

buprenorphine alcoholic solution, 1-alpha-acetylmethadol concentrate,

naltrexone sustained-release preparations).  These drugs are acquired

by the Government from private industry, Government

contractors/grantees, or independent investigators.  In order to ensure

the identity, strength, quality and purity of these materials, the

Government has been performing quality control tests before

distributing them to the research community.  The purpose of this

procurement is to solicit a contractor to develop analytical methods,

carry out quality control tests, dosage form preparation, and perform

stability studies for the compounds and dosage forms to be used in the

medications development program.  The offeror is required to submit

documentation of possession of a DEA research registration for Schedule

I and II-V controlled substances with their response to the Request for

Proposal (RFP).



It is estimated that the RFP will result in a four-year incrementally

funded completion-type contract with an option for a fifth year, as

well as options for additional compound analysis and testing.

Estimated issuance date of RFP No. NO1DA-3-8301 is March 22, 1993, and

responses are due to be received in the Contracting Officer 45 calendar

days thereafter.  Written requests for copies of solicitations will be

honored if received within twenty calendar days after issuance of the

solicitation.  Requests received after this period will be filled on a

first-come, first-served basis until the supply is exhausted; however,

there is no assurance that copies requested after the twentieth day

will reach the requestor before the due date for receipt of responses.



INQUIRIES



Requests are to be forwarded to:



Brenda Brooks, Contract Specialist

National Institute on Drug Abuse

Parklawn Building, Room 10-49

5600 Fishers Lane

Rockville, MD  20857



.

Return to 1993 Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.